Core Viewpoint - The announcement from Recbio Biotech regarding the resignation of founder Dr. Liu Yong as Chairman and the appointment of Xu Haoyu as the new Chairman highlights a significant leadership change within the company [1] Group 1: Leadership Change - Dr. Liu Yong has resigned from his positions as Chairman and Chairman of the Nomination Committee of Recbio Biotech [1] - Xu Haoyu, aged 53, has been elected as the new Chairman and is currently the Chairman of Yangtze River Pharmaceutical Group [1] - Xu Haoyu has over 30 years of experience in the pharmaceutical industry and has held various positions within Yangtze River Pharmaceutical Group since 1994 [1] Group 2: Xu Haoyu's Background - Xu Haoyu graduated from Shanghai University of Applied Technology in 1994 and obtained an MBA from Maastricht School of Management in 2002 [1] - He has served in multiple roles at Yangtze River Pharmaceutical Group, including Sales Officer, Provincial Company Manager, Deputy Director, and Vice Chairman [1] - Since July 2021, Xu has held the positions of Party Secretary, Chairman, and President at Yangtze River Pharmaceutical Group [1] Group 3: Shareholding Structure - Xu Haoyu does not receive a salary from Recbio Biotech, except for reasonable remuneration for specific services provided [1] - His spouse, Zhu Yuqing, directly holds 3.161 million H-shares, and he has control over additional shares through associated enterprises [1] - Yangtze River Pharmaceutical Group holds 143 million domestic shares, while Yangtze River (Hong Kong) Limited holds 12.6185 million H-shares [1]
瑞科生物：扬子江药业集团董事长徐浩宇获选公司新任董事长